Trial drug for treatment of fatigue in MS. Don't know what their other MS drugs are or what phase they are in.
MultiCell to Present Company's Portfolio of Novel Drug Candidates at BIO 2006 Conference; Company President Dr. Stephen Chang to Discuss Novel Therapeutic Candidates Targeting Multiple Sclerosis, Diabetes and Other Medical Needs
SAN DIEGO--(BUSINESS WIRE)--April 10, 2006 - MultiCell Technologies, Inc. (OTCBB:MCET), developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases, today announced that Company President Dr. Stephen Chang will present an overview of MultiCell's drug development pipeline and partnership opportunities at the BIO 2006 biotechnology conference.
At BIO 2006, one of the industry's leading annual forums, Dr. Chang will outline the Company's portfolio of drug candidates, therapeutic indications and target markets. MultiCell's lead drug candidate MCT-125 has been shown to be effective in Phase II clinical trials for the treatment of fatigue in multiple sclerosis patients. MultiCell expects to commence a Phase IIb/III trial later this year for MCT-125. MultiCell's autoimmune disease focused portfolio also includes therapeutic compounds designed to treat the primary symptoms of multiple sclerosis and Type-1 diabetes.
"I look forward to discussing MultiCell's drug development initiatives and opportunities for growth and expansion of our drug development pipeline," said Dr. Chang. "The data from pre-clinical and clinical programs involving our drug candidates so far have been encouraging the potential worldwide markets for our compounds are large."
Representatives from other biotechnology companies, and from major government and leading research institutions, will be in attendance. BIO 2006 is scheduled to run April 9-12 in Chicago at the McCormick Place Convention Center.
Dr. Chang is scheduled to make the MultiCell presentation on Tuesday, April 11, at 4:30 p.m. in Room B.
About BIO 2006
The BIO 2006 conference is organized by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. For more information on the BIO 2006 Annual International Convention, visit http://www.bio.org/events/2006
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology platforms. The Company's drug development programs are focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat fatigue resulting from multiple sclerosis, relapse-remitting multiple sclerosis, and type-1 diabetes. Other therapeutic candidates in the MultiCell development pipeline include new antiviral treatments to address worldwide influenza threats as well as treatments for other infectious diseases. The Company also holds unique cell-based technology for use in drug discovery screening applications and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information on MultiCell, please visit http://www.multicelltech.com
Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development of MCT-125, and statements regarding expected milestone and royalty payments to Amarin and worldwide sales relating to MCT-125. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize MCT-125 as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.